Cargando…

Probiotics and live biotherapeutic products aiming at cancer mitigation and patient recover

Molecular biology techniques allowed access to non-culturable microorganisms, while studies using analytical chemistry, as Liquid Chromatography and Tandem Mass Spectrometry, showed the existence of a complex communication system among bacteria, signaled by quorum sensing molecules. These approaches...

Descripción completa

Detalles Bibliográficos
Autores principales: Schemczssen-Graeff, Zelinda, Pileggi, Marcos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395637/
https://www.ncbi.nlm.nih.gov/pubmed/36017495
http://dx.doi.org/10.3389/fgene.2022.921972
_version_ 1784771743083134976
author Schemczssen-Graeff, Zelinda
Pileggi, Marcos
author_facet Schemczssen-Graeff, Zelinda
Pileggi, Marcos
author_sort Schemczssen-Graeff, Zelinda
collection PubMed
description Molecular biology techniques allowed access to non-culturable microorganisms, while studies using analytical chemistry, as Liquid Chromatography and Tandem Mass Spectrometry, showed the existence of a complex communication system among bacteria, signaled by quorum sensing molecules. These approaches also allowed the understanding of dysbiosis, in which imbalances in the microbiome diversity, caused by antibiotics, environmental toxins and processed foods, lead to the constitution of different diseases, as cancer. Colorectal cancer, for example, can originate by a dysbiosis configuration, which leads to biofilm formation, production of toxic metabolites, DNA damage in intestinal epithelial cells through the secretion of genotoxins, and epigenetic regulation of oncogenes. However, probiotic strains can also act in epigenetic processes, and so be use for recovering important intestinal functions and controlling dysbiosis and cancer mitigation through the metabolism of drugs used in chemotherapy, controlling the proliferation of cancer cells, improving the immune response of the host, regulation of cell differentiation and apoptosis, among others. There are still gaps in studies on the effectiveness of the use of probiotics, therefore omics and analytical chemistry are important approaches to understand the role of bacterial communication, formation of biofilms, and the effects of probiotics and microbiome on chemotherapy. The use of probiotics, prebiotics, synbiotics, and metabiotics should be considered as a complement to other more invasive and hazard therapies, such chemotherapy, surgery, and radiotherapy. The study of potential bacteria for cancer treatment, as the next-generation probiotics and Live Biotherapeutic Products, can have a controlling action in epigenetic processes, enabling the use of these bacteria for the mitigation of specific diseases through changes in the regulation of genes of microbiome and host. Thus, it is possible that a path of medicine in the times to come will be more patient-specific treatments, depending on the environmental, genetic, epigenetic and microbiome characteristics of the host.
format Online
Article
Text
id pubmed-9395637
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93956372022-08-24 Probiotics and live biotherapeutic products aiming at cancer mitigation and patient recover Schemczssen-Graeff, Zelinda Pileggi, Marcos Front Genet Genetics Molecular biology techniques allowed access to non-culturable microorganisms, while studies using analytical chemistry, as Liquid Chromatography and Tandem Mass Spectrometry, showed the existence of a complex communication system among bacteria, signaled by quorum sensing molecules. These approaches also allowed the understanding of dysbiosis, in which imbalances in the microbiome diversity, caused by antibiotics, environmental toxins and processed foods, lead to the constitution of different diseases, as cancer. Colorectal cancer, for example, can originate by a dysbiosis configuration, which leads to biofilm formation, production of toxic metabolites, DNA damage in intestinal epithelial cells through the secretion of genotoxins, and epigenetic regulation of oncogenes. However, probiotic strains can also act in epigenetic processes, and so be use for recovering important intestinal functions and controlling dysbiosis and cancer mitigation through the metabolism of drugs used in chemotherapy, controlling the proliferation of cancer cells, improving the immune response of the host, regulation of cell differentiation and apoptosis, among others. There are still gaps in studies on the effectiveness of the use of probiotics, therefore omics and analytical chemistry are important approaches to understand the role of bacterial communication, formation of biofilms, and the effects of probiotics and microbiome on chemotherapy. The use of probiotics, prebiotics, synbiotics, and metabiotics should be considered as a complement to other more invasive and hazard therapies, such chemotherapy, surgery, and radiotherapy. The study of potential bacteria for cancer treatment, as the next-generation probiotics and Live Biotherapeutic Products, can have a controlling action in epigenetic processes, enabling the use of these bacteria for the mitigation of specific diseases through changes in the regulation of genes of microbiome and host. Thus, it is possible that a path of medicine in the times to come will be more patient-specific treatments, depending on the environmental, genetic, epigenetic and microbiome characteristics of the host. Frontiers Media S.A. 2022-08-09 /pmc/articles/PMC9395637/ /pubmed/36017495 http://dx.doi.org/10.3389/fgene.2022.921972 Text en Copyright © 2022 Schemczssen-Graeff and Pileggi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Schemczssen-Graeff, Zelinda
Pileggi, Marcos
Probiotics and live biotherapeutic products aiming at cancer mitigation and patient recover
title Probiotics and live biotherapeutic products aiming at cancer mitigation and patient recover
title_full Probiotics and live biotherapeutic products aiming at cancer mitigation and patient recover
title_fullStr Probiotics and live biotherapeutic products aiming at cancer mitigation and patient recover
title_full_unstemmed Probiotics and live biotherapeutic products aiming at cancer mitigation and patient recover
title_short Probiotics and live biotherapeutic products aiming at cancer mitigation and patient recover
title_sort probiotics and live biotherapeutic products aiming at cancer mitigation and patient recover
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395637/
https://www.ncbi.nlm.nih.gov/pubmed/36017495
http://dx.doi.org/10.3389/fgene.2022.921972
work_keys_str_mv AT schemczssengraeffzelinda probioticsandlivebiotherapeuticproductsaimingatcancermitigationandpatientrecover
AT pileggimarcos probioticsandlivebiotherapeuticproductsaimingatcancermitigationandpatientrecover